DUBAG Group-backed LEO III Fund completed the acquisition of PronoKal from Nestlé Health Science.

DUBAG Group-backed LEO III Fund, a vintage credit special situations fund, completed the acquisition of PronoKal, a company that provides weight loss products and services, from Nestlé Health Science, a company engaged in advancing the role of nutritional therapy in the management of people’s health. Financial terms were not disclosed. “We are proud to have acquired PronoKal from Nestlé Health Science. PronoKal combines a unique scientific approach with strong market potential. Together with the management team, we will drive innovation and support the company’s growth journey, positioning PronoKal as the global leader in ketogenic nutrition,” Michael Schumann, DUBAG Group CEO.